Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
Public ClinicalTrials.gov record NCT01163526. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A research study of liver perfusion (how blood flows to the liver over time). We hope to learn whether perfusion characteristics of liver masses may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment.
Study identification
- NCT ID
- NCT01163526
- Recruitment status
- Terminated
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 13 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2010
- Primary completion
- Jun 30, 2016
- Completion
- Jun 30, 2016
- Last update posted
- Jan 29, 2017
2010 – 2016
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University School of Medicine | Stanford | California | 94305 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Neuroendocrine Tumors trials
Other public records listing Neuroendocrine Tumors. Sorted by last update posted; newest first. Not a recommendation.
- NCT06448208: Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors Active, not recruiting
- NCT05000294: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Recruiting
- NCT02012699: Integrated Cancer Repository for Cancer Research Recruiting
- NCT07661420: 211At-MABG in Adults With Advanced Neuroendocrine Cancers Not yet recruiting
- NCT03935893: Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers Active, not recruiting
- NCT06122610: Using Novel Imaging to More Safely Treat Neuroendocrine Tumors Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01163526, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 29, 2017 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01163526 live on ClinicalTrials.gov.